Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 167 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Enbrel Clear all
Completed Phase 1 Interventional

TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset

NCT04254627
View directory record Official record
Conditions
Gulf War Illness
Interventions
Etanercept, Mifepristone
Drug
Lead sponsor
Nova Southeastern University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Davie, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia

NCT00965666
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Etanercept
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 19, 2026, 5:30 PM EDT
Recruiting Phase 3 Interventional

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

NCT03414502
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Study Evaluating Etanercept in Moderate to Severe Asthma

NCT00141791
View directory record Official record
Conditions
Asthma
Interventions
Etanercept
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
13
States / cities
Birmingham, Alabama • Denver, Colorado • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

Study of TNF-Antagonism in the Metabolic Syndrome (II)

NCT00413400
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

NCT02464878
View directory record Official record
Conditions
Kidney Transplant, Type 1 Diabetes
Interventions
Alpha 1-Antitrypsin, Islet Transplantation, Thymoglobulin, Basiliximab, Etanercept
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease

NCT01716637
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Etanercept, Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Biological · Dietary Supplement
Lead sponsor
Life Extension Foundation Inc.
Other
Eligibility
60 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Coral Springs, Florida • Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

NCT00309907
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
etanercept, methylprednisolone
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00691964
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ABT-874, etanercept, placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
35
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer

NCT00046904
View directory record Official record
Conditions
Anorexia, Cachexia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
etanercept
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
19
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Oct 19, 2026, 5:30 PM EDT
Withdrawn Not applicable Interventional

TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial

NCT02031211
View directory record Official record
Conditions
CRPS, Chronic Regional Pain Syndrome
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 17 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis

NCT00800982
View directory record Official record
Conditions
Psoriasis
Interventions
Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

NCT03915964
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, TNF Inhibitor
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
81
States / cities
Flagstaff, Arizona • Gilbert, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy

NCT00733096
View directory record Official record
Conditions
Lumbosacral Radiculopathy
Interventions
etanercept, methylprednisolone, normal saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 19, 2026, 5:30 PM EDT
Active, not recruiting No phase listed Observational

Psoriasis Longitudinal Assessment and Registry

NCT00508547
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
20,167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
167
States / cities
Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

NCT02115750
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, CHS-0214
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
37
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 19, 2026, 5:30 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 19, 2026, 5:30 PM EDT
Not listed Phase 4 Interventional

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

NCT01793519
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Infliximab, Adalimumab, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional

Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT00201682
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Etanercept, Rituximab
Drug
Lead sponsor
John Byrd
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

NCT01971346
View directory record Official record
Conditions
Psoriasis
Interventions
etanercept
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 19, 2026, 5:30 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

NCT00293202
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Kaysen, George A., M.D., Ph.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis

NCT00116181
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2011 · Synced Oct 19, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Biological Therapy in Treating Patients With Myelodysplastic Syndrome

NCT00005853
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, etanercept
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 19, 2026, 5:30 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

NCT03451851
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo for guselkumab, Etanercept
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Palo Alto, California • San Diego, California • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 5:30 PM EDT